Sign in Create account

CENTUPLE GLOBAL LIMITED

Healthcare · Pharmaceuticals & Biotechnology

BSE: 531099
₹31.48
▲ 0.23 (0.74%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
53/100
Moderate
Valuation
67/100
Fairly Valued
Momentum
49/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹17 Cr
PE (TTM)
8.9
Industry median 36.1 (152 companies)
Price to Book
8.3
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
127.3
Free Cash Flow
₹-28 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-125.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
1593.26%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
4637.13%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-858.73%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
111666.00%
as of March 31, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.07
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
3.26
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
20101.00
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-0.17%
as of March 31, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-0.13%
as of March 31, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
0.35%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
0.44%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
9.82%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
72.97%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 5 met
  • No Quality score is Strong (70 or more)
  • No Debt to equity is below 0.5 (3.26)
  • Yes Return on equity is 15% or more (73.0%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.7%
Low 29.6900 · High 32.7500
1W return
-5.7%
Low 29.6900 · High 33.9500
1M return
-13.3%
Low 28.4200 · High 37.6600
52W return
127.3%
Low 28.4200 · High 63.7900
Lifetime High ₹77.8000 (May 31, 2010)
Lifetime Low ₹0.9600 (April 7, 2014)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
31.9
10D
32.4
20D
33.0
50D
29.9
100D
23.6
200D
13.6

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

31.31
Pivot
First resistance32.92
Second resistance34.37
Third resistance35.98
First support29.86
Second support28.25
Third support26.80
Day RSI46.2
Day MFI67.5
Day MACD-0.24
Day MACD signal0.27

Beta

1M-0.10
3M-0.52
1Y-0.52
3Y0.39

Price change analysis

↓ -13.3%
Over 1 Month
LowHigh
28.4237.66
↑ 127.3%
Over 3 Months
LowHigh
28.4263.79
↑ 127.3%
Over 6 Months
LowHigh
28.4263.79
↑ 127.3%
Over 1 Year
LowHigh
28.4263.79
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 8.9 (own history: 3.7–173.1)
Buy Zone

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹— Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹-0.0400

Ranks #167 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • FII/FPI11.15%

Largest holders

Data unavailable.

Historical promoter holding

Historical fii holding

FII/FPI holdings increased from 8.59% to 11.15% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 183 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
21 Sep 2026 RAJVANSH ELECTRICALS PRIVATE LIMITED Bulk Sell 60,656 31.3500 BSE
13 Apr 2026 AMAYVATSALYA Bulk Sell 45,000 53.0000 BSE
9 Apr 2026 AMAYVATSALYA Bulk Sell 69,465 47.5000 BSE
8 Apr 2026 NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE Bulk Buy 50,000 43.2000 BSE
8 Apr 2026 AMAYVATSALYA Bulk Sell 56,613 43.2000 BSE
20 Mar 2026 NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE Bulk Sell 27,500 54.7600 BSE
18 Mar 2026 NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE Bulk Sell 48,500 49.6800 BSE
6 Mar 2026 NOVA GLOBAL OPPORTUNITIES FUND PCC - TOUCHSTONE Bulk Sell 40,000 59.3300 BSE
9 Dec 2025 MULTIPLIER SHARE & STOCK ADVISORS PRIVATE LIMITED Bulk Sell 35,377 113.9700 BSE
9 Dec 2025 MALINI PRADEEP SAXENA Bulk Buy 55,000 113.9700 BSE

All bulk and block deals →

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Checkpoint Trends Limited to CENTUPLE GLOBAL LIMITED
—NAME_CHANGEName changed from Rubra Medicaments Ltd. to RUBRA MEDICAMENTS LTD.

All corporate actions →

Corporate Announcements

All 8 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Centuple Global Ltd - 531099 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct 2026 AGM/EGM Centuple Global Ltd - 531099 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 AGM/EGM Centuple Global Ltd - 531099 - Proceeding Of The 35Th Annual General Meeting Held On Wednesday, September 30, 2026 Through Video Conferencing (VC) / Other Audio Visual Means (OAVM).
21 Sep 2026 Insider Trading / SAST Centuple Global Ltd - 531099 - Closure of Trading Window
8 Sep 2026 Company Update Centuple Global Ltd - 531099 - Announcement under Regulation 30 (LODR)-Newspaper Publication
5 Sep 2026 AGM/EGM Centuple Global Ltd - 531099 - Notice Of AGM
5 Sep 2026 Board Meeting Centuple Global Ltd - 531099 - Board Meeting Outcome for Outcome Of Board Meeting
5 Sep 2026 Others Centuple Global Ltd - 531099 - Reg. 34 (1) Annual Report.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (73.0%)
  • Comfortable interest coverage (20101.0x)
  • Strong revenue growth YoY (111666.0%)

Weaknesses

  • Thin net profit margin (-0.2%)
  • High financial leverage (Debt/Equity 3.26)
  • Declining profit YoY (-858.7%)

Opportunities

  • PEG below 1 (0.01) -- earnings growth outpacing its own valuation
  • PE below 15 (8.9) relative to a typical growth business

Threats

Data unavailable.

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about CENTUPLE GLOBAL LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.